This company is no longer active
PhaseBio Pharmaceuticals Management
Management criteria checks 3/4
PhaseBio Pharmaceuticals' CEO is Jonathan Mow, appointed in Mar 2015, has a tenure of 7.92 years. total yearly compensation is $1.53M, comprised of 36.7% salary and 63.3% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth €513.08. The average tenure of the management team and the board of directors is 3.3 years and 4.4 years respectively.
Key information
Jonathan Mow
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 36.7% |
| CEO tenure | 7.9yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$562k | -US$131m |
| Sep 30 2021 | n/a | n/a | -US$118m |
| Jun 30 2021 | n/a | n/a | -US$112m |
| Mar 31 2021 | n/a | n/a | -US$111m |
| Dec 31 2020 | US$2m | US$529k | -US$99m |
| Sep 30 2020 | n/a | n/a | -US$80m |
| Jun 30 2020 | n/a | n/a | -US$66m |
| Mar 31 2020 | n/a | n/a | -US$47m |
| Dec 31 2019 | US$1m | US$436k | -US$39m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$27m |
| Dec 31 2018 | US$596k | US$359k | -US$24m |
| Sep 30 2018 | n/a | n/a | -US$22m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$436k | US$338k | -US$10m |
Compensation vs Market: Jonathan's total compensation ($USD1.53M) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
CEO
Jonathan Mow (57 yo)
7.9yrs
Tenure
US$1,529,108
Compensation
Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceutical...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.9yrs | US$1.53m | 0.37% € 513.1 | |
| Chief Medical Officer | 6.8yrs | US$856.30k | 0% € 0 | |
| Chief Restructuring Officer & Principal Financial Officer | less than a year | no data | no data | |
| Senior Vice President of Technical Operations | 1.3yrs | no data | 0.083% € 115.2 | |
| SVP, General Counsel & Corporate Secretary | 3.3yrs | no data | 0.017% € 23.6 | |
| Senior Vice President of Human Resources | 3.3yrs | no data | no data | |
| Global Head of Regulatory Affairs & Quality Assurance | no data | no data | no data | |
| Chief Commercial Officer | 1.3yrs | no data | 0.040% € 55.9 |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: 2K4's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.4yrs | US$1.53m | 0.37% € 513.1 | |
| Independent Director | 4yrs | US$82.86k | 0% € 0 | |
| Independent Director | 4.2yrs | US$76.36k | 0.012% € 16.8 | |
| Independent Chairman of the Board | 21.1yrs | US$116.36k | 0.066% € 92.0 | |
| Independent Director | 1.4yrs | US$62.58k | 0% € 0 | |
| Independent Director | 4.6yrs | US$85.36k | 0% € 0 | |
| Independent Director | 4.9yrs | US$87.36k | 0.076% € 105.5 | |
| Independent Director | 3yrs | US$77.86k | 0% € 0 |
4.4yrs
Average Tenure
56yo
Average Age
Experienced Board: 2K4's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/15 15:31 |
| End of Day Share Price | 2022/11/18 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PhaseBio Pharmaceuticals, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Chad Messer | Needham & Company |
| Annabel Samimy | Stifel, Equities Research |